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Abstract  34 
 35 
DNA methylation and histone deacetylation are key epigenetic processes involved in normal cellular 36 
function and tumorigenesis. Therapeutic strategies based on DNA methyltransferase (DNMT) and histone 37 
deacetylase (HDAC) inhibitors are currently in use and under development for the treatment of cancers. 38 
Genome-wide DNA methylation profiling has been proposed for use in disease diagnosis, and histone 39 
modification profiling for disease stratification will follow suit. However, whether epigenome sequencing 40 
technologies will be feasible for rapid clinic diagnosis and patient treatment monitoring remains to be seen, 41 
and alternative detection technologies will almost certainly be needed. Here we used electrochemical 42 
impedance spectroscopy (EIS) employing a graphene-based screen-printed electrode system to directly 43 
measure global DNA methylation and histone H3 acetylation to compare non-cancer and breast cancer cell 44 
lines. We demonstrated that whilst global methylation was not useful as a differential marker in the 45 
cellular systems tested, histone H3 acetylation was effective at higher chromatin levels. Using breast and 46 
endometrial cancer cell models, EIS was then used to monitor cellular responses to the DNMT and HDAC 47 
inhibitors 5-Aza-2′-deoxycytidine and suberoylanilide hydroxamic acid in vitro, and proved very effective 48 
at detecting global cellular responses to either treatment, indicating that this approach could be useful in 49 
following treatment response to epigenetic drugs. Moreover, this work reports the first combined analysis 50 
of two epigenetic markers using a unified graphene-based biosensor platform, demonstrating the potential 51 
for multiplex analysis of both methylation and acetylation on the same sample. 52 
 53 
 54 
1. Introduction 55 
 56 
Cancer cells undergo epigenetic changes in 5-methylcytosine distribution that include global DNA 57 
hypomethylation and the hypermethylation of promoter CpG islands associated with tumor-suppressor 58 
genes. DNA methylation is just one facet in the coordinated regulation of chromatin structure that also 59 
involves discrete modifications to histone proteins, including histone H3 and H4 deacetylation, among 60 
others, which collectively result in transcriptionally altered states (Capp, 2017; Jones and Baylin, 2007; Lo 61 
and Zhou, 2018; Sheahan and Ellis, 2018). 62 
 63 
Large-scale epigenomic studies have been made possible using established complex technologies. These 64 
allow the genome-wide mapping of epigenetic marks, including DNA methylation and histone 65 
modifications, which are critical for regulating gene expression. In turn, we are learning how mapping 66 
aberrant alterations to these epigenetic marks can be used in clinical diagnostics (Bock et al., 2016; Butler 67 
and Dent, 2013; Libertini et al., 2016; Rendeiro et al., 2016). 68 
 69 
DNA methylation and histone modification biomarkers have several advantages that qualify them for 70 
broad use as in vitro diagnostics and to support clinical decisions: (i) They can be cell-type-specific, yet 71 
robust toward transient perturbations. (ii) They are binary marks (i.e., for a single cell and allele, an 72 
epigenetic mark is either modified or not), which facilitates reliable measurements on heterogeneous 73 
samples. (iv) The use of epigenetic markers to detect cancer sensitively is based on the premise that tumor-74 
derived chromatin/DNA is released into bodily fluids, or other remote samples, and can be detected by 75 
abnormal DNA methylation and histone modification patterns (Bormann et al., 2018; Coleman and De, 76 
2018; Graff-Baker et al., 2018; Singh et al., 2018; Xi et al., 2018; Zhang et al., 2018). 77 
 78 
Current approaches to assess the epigenetic state currently target individual genetic loci to determine 79 
histone modification (predominantly acetylation and methylation) and DNA methylation status. Bisulphite 80 
sequencing has been the mainstay of DNA methylation analysis with methylated and hydroxymethylated 81 
DNA immunoprecipitation (MeDIP and (h)MeDIP) methods coming online, whilst chromatin 82 
immunoprecipitation (ChIP) is the research tool of choice for determining histone modifications. However, 83 
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these approaches are yet to become a clinically useful diagnostic methods due to their time-consuming 84 
nature, and where genome-wide DNA sequencing is used (bisulphite and ChIP/MeDIP – seq), the 85 
generation of more data than is needed for diagnosis or monitoring therapeutic response. Other approaches 86 
include serum proteomics using mass spectrometry that whilst progressing in clinical feasibility studies, 87 
require expensive and highly technical hardware, and expert users for sample and data analysis. 88 
 89 
Electrochemical immunosensors using advances in nanomaterials are being developed for biosensing 90 
applications (Zhu et al., 2015). For the detection of epigenetic modifications electrochemical analytical 91 
methods offer several advantages over other techniques, such as surface plasmon resonance and atomic 92 
force spectroscopy, in terms of sensitivity, simplicity and portability (Stewart and Tsui, 2018). 93 
Furthermore, they offer limits of detection of methylated DNA within the levels reported to be found 94 
circulating in plasma (Stewart and Tsui, 2018). In addition, instrumentation required to make such 95 
measurements is low-cost, with instrument refinement reducing costs even further (Sawhney and Conlan, 96 
2019). Gold and carbon -based electrode systems remain the most utilized working electrode materials, 97 
despite many other materials having been evaluated (Krejcova et al., 2017), and have been used in screen 98 
printed formats that offer low cost per unit, and do not require extensive preparation to obtain a pristine 99 
surface prior to use. Graphene as a working electrode offers a high signal to noise ratio, and is easily 100 
functionalized with antibodies when coated with polyaniline, which also serves a conductive polymer and 101 
is used as an additive transducer layer to avoid the introduction of graphene surface defects (Gazze et al., 102 
2018; Teixeira et al., 2014a). Graphene offers a further advantage over gold electrodes for the detection 103 
and quantification of DNA as it lacks the inherent absorption properties for unmodified DNA that are 104 
displayed by gold surfaces due to affinity interactions (Koo et al., 2015).  Here, we demonstrate the use of 105 
a graphene-based immunosensor, where anti-5-methylcytosine (anti-5mc) and anti-acetylated histone H3 106 
(anti-acH3) antibodies were directly coupled to a polyaniline-modified screen-printed graphene electrode 107 
to detect DNA and chromatin using label-free EIS measurements. Using this system global levels of 108 
methylated DNA and histone H3 acetylated chromatin levels were assessed in normal (MCF12A) and 109 
cancer (MCF7) breast cell models, and MCF7 and HEC50 cells treated with a DMNT or HDAC inhibitors 110 
were found to show alterations in DNA methylation or histone H3 acetylation respectively. Overall, this 111 
study highlights the effectiveness EIS graphene immune sensors for the direct label- and amplification-free 112 
detection of global epigenetic modifications in cancer cells, and thus their potential for monitoring 113 
therapeutic efficacy. 114 
 115 
2. Materials and Methods 116 
 117 
Cell culture and treatments. MCF7 cells (ATCC, Maryland USA) were cultured in Eagle’s Minimum 118 
Essential Medium (Gibco, ThermoFisher Scientific, UK) supplemented with 10% (v/v) foetal bovine 119 
serum (Gibco) and 0.01mg/ml insulin (Sigma-Aldrich, Missouri, USA). Hec50 cells (ATCC, Maryland 120 
USA) were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) (Gibco, 121 
ThermoFisher Scientific, UK) supplemented with 10% (v/v) fetal bovine serum (Gibco), 1% (v/v) 122 
penicillin and streptomycin (Gibco), sodium bicarbonate and sodium pyruvate. MCF12A cells (ATCC, 123 
Maryland USA) were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 124 
(DMEM/F12) (Gibco, ThermoFisher Scientific, UK) supplemented with 5% (v/v) horse serum (Gibco), 125 
20ng/ml human epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml bovine insulin and 500 126 
ng/ml hydrocortisone 95%. All cell lines were grown at 37°C in a humidified atmosphere with 5% CO2 to 127 
90% confluency in T75 flasks (Corning, New York, USA) before collection. Cells were grown to 40% or 128 
60% confluency respectively before exchanging full growth media for stripped media prior to treatment 129 
with the DNMT inhibitor 5-Aza-2′-deoxycytidine (1 µM), suberoylanilide hydroxamic acid (2.5 µM) or 130 
vehicle (DMSO).  131 
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 132 
Chromatin and genomic DNA extraction. Chromatin and gDNA were extracted using the Chromatrap® 133 
ChIP seq kit chromatin preparation reagents and the Chromatrap® MeDIP kit gDNA preparation reagents 134 
according to the manufacturer’s instructions (Porvair Sciences Ltd, Wrexham, UK). 135 
 136 
Immunosensor assembly. Graphene-SPEs were purchased from DropSens (DRP-110GPH Metrohm UK 137 
Ltd, Runcorn, UK) and were composed of a carbon counter electrode, a silver pseudo-reference electrode, 138 
and a printed graphene working electrode (4 mm ∅). Electrical characterization of SPEs was performed by 139 
connecting the SPEs to the potentiostat/galvanostat via a suitable switch box (DropSens, Metrohm UK Ltd, 140 
Runcorn, UK). In order to mediate selective immunodetection of chromatin and gDNA to the graphene 141 
sensor surface, PANI functionalization was utilized, as previously described  (Teixeira et al., 2014b).  142 
 143 
Electrochemical measurements. CV and EIS were performed using a Metrohm Autolab PGSTAT302N 144 
equipped with FRA32M and DRP-DSC connector; control and analysis were provided through Nova 145 
software version 2.0.1 and higher (Metrohm UK Ltd, Runcorn, UK). CV procedures spanned -0.7 to 0.7 146 
Volts starting and ending at 0V with a scan rate of 0.05 Volts per second. EIS procedures applied 50 147 
frequencies between 1000 and 0.01 hertz, logarithmically distributed at an amplitude of 0.01 VRMS on a DC 148 
bias of 0.1V with the reference electrode. EIS data was fitted to a R(C[R(RC)]) equivalent circuit model 149 
using a maximum of 300 iterations with weight factor applied. 150 
 151 
Chromatin/gDNA detection and quantification.  The functionalized biosensing platforms are based on 152 
impedance measurements resulting in changes of resistivity (Rct) following the binding of a chromatin.  153 
or gDNA to the specific antibody immobilized on the sensor surface. Increasing concentrations of 154 
chromatin ranging from 0.0086 to 134 ng/µL for MCF12A, 0.0078 to 123 ng/µL for MCF7 and 0.0053 to 155 
416 ng/µL for Hec50; and gDNA solutions, ranging from 0.0048 to 75 ng/µl for all cell lines, were 156 
prepared by dilution of 1708 ng/µL of chromatin and 75 ng/µL of gDNA stock solutions in media.  157 
Chromatin immunoprecipitation. ChIP assays were performed using the Chromatrap® ChIP-seq kit 158 
following the manufacturers’ instructions (Porvair Sciences Ltd, Wrexham, UK). Chromatin was 159 
quantified by Nanodrop 2000 (ThermoFisher Scientific) and visualized using by agarose gel 160 
electrophoresis to ensure correct distribution of fragment sizes prior to immunoprecipitation. 1 µg of each 161 
chromatin sample was used per ChIP with 2 µg of relevant antibody; anti acetyl H3 antibody (Millipore, 162 
Darmstadt, Germany) or non-specific rabbit IgG (Chromatrap, Porvair Sciences Ltd, Wrexham, UK). 163 
qPCR was carried on the target gene p21 forward primer 5’-CCCACAGCAGAGGAGAAAGAA; reverse 164 
primer 5’-CTGGAAATCTCTGCCAGACA.  165 
Methylated DNA immunoprecipitation. MeDIP assays were carried out using the Chromatrap MeDIP kit 166 
according to the manufacturers’ protocol (Porvair Sciences Ltd, Wrexham, UK). gDNA was quantified by 167 
Nanodrop 2000 (ThermoFisher Scientific) and visualized using agarose gel electrophoresis to ensure 168 
correct distribution of fragment sizes prior to immunoprecipitation. 500 ng DNA was used per MeDIP with 169 
1µg kit supplied anti-5-methylcytosine antibody or non-specific mouse IgG and linker. Samples were 170 
neutralized, and amplification of enriched methylated DNA carried out at the CXCL12 locus forward 171 
primer 5’-CTCATTCAGTTCCCGCCATC; reverse primer 5’-GCCGCTTATTGTCCCTGTG. 172 
Western blotting.  Total protein was extracted using RIPA buffer and quantified using the DC Protein 173 
assay (BioRad, Watford, UK). Relevant protein concentrations were separated by SDS PAGE. Proteins 174 
were transferred to PVDF membrane, blocked and probed with a 1/15,000 dilution of anti-acetyl H3 175 
antibody (Millipore, Watford, UK) followed by ECL anti-rabbit IgG horse radish peroxidase (GE 176 
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Healthcare, Bucks, UK). Bands were developed using the Clarity Western ECL Substrate (Biorad, 177 
Watford, UK) chemiluminescence kit and visualized using a ChemiDoc (BioRad, Watford, UK).  178 
Dot blotting. gDNA extracted and sheared as described for the MeDIP protocol was used for dot blotting. 179 
Immun-Blot PVDF Membrane (BioRad, Watford, UK) was activated with methanol and equilibrated with 180 
transfer buffer prior to spotting the membrane with 100ng heat denatured gDNA. A 1/300 dilution of the 181 
primary antibody anti-5mC (Chromatrap Porvair Sciences Ltd, Wrexham, UK) was used to probe the 182 
methylated DNA and detected with ECL anti-rabbit IgG horse radish peroxidase (GE Healthcare, Bucks, 183 
UK).  184 
3. Results 185 
 186 
Immunosensor assembly and functionalization 187 
 188 
Electrochemical impedance spectroscopy (EIS) is a label and amplification free technique that enables 189 
direct molecular measurements on modified surface electrodes (Sánchez et al., 2008). Here, we adapted 190 
our previously reported screen-printed electrode (SPE)-graphene/polyaniline (PANI) platform to detect 191 
methylated DNA and acetylated histone H3 using anti-5mc and anti-acH3 antibodies respectively. Sensor 192 
optimization using control DNA and chromatin extracted from cell line models established sensitivity 193 
according to our established protocols (Teixeira et al., 2016). 194 
 195 
Sensor assembly was evaluated using scanning electron microscopy and atomic force microscopy (Fig. 196 
S1), and electron transfer properties determined against a redox probe and evaluated by cyclic 197 
voltammetry (CV) and EIS. Unmodified graphene-SPEs showed a quasi-reversible electrochemical 198 
response for the [Fe(CN)6]3-/4- redox couple with ∆Ep of 0.158 V and ∆Ip of 0.285 mA, respectively. After 199 
10 cycles, the modification of graphene-SPE surface with PANI resulted in a ∆Ip increase of 0.894 mA 200 
and a ∆Ep decrease of 2.898 V (Fig. 1A) attributed to positively charged amino groups of the PANI 201 
molecule attracting the negative charge of [Fe(CN)6]3-/4- promoting electron transfer on the electrode 202 
surface (Zor et al., 2013). A cyclic voltammogram of the SPE-graphene/PANI/Antibody electrode showed 203 
a decrease peak-to-peak potential separation (∆Ep of 0.547 V). Further, addition of the BSA blocking 204 
agent to the SPE-graphene/PANI/Ab electrode surface gave rise to a change on the electrochemical 205 
behavior of [Fe(CN)6]3-/4-, leading to a ∆Ep increase of 0.258 V and decreased ∆Ip value of 0.546 mA. 206 
BSA molecules cause masking of the electrode surface oxidation/reduction of the redox probe [Fe(CN)6]3-207 
/4-
 (Daniels and Pourmand, 2007).  208 
 209 
EIS data are presented as Nyquist plots where the Rct at the electrode surface is given by the hemicircle 210 
diameter obtained in EIS and can be used to define the interface properties of the electrode. The 211 
unmodified graphene surface display fast electron-transfer properties (Rct = 884 Ω, Fig. 1B), which 212 
increases following PANI deposition (Rct = 1.13 KΩ, Fig. 1B). Following covalent attachment of anti-213 
acH3 antibody, the Rct increased to 1.82 KΩ (Fig. 1B), demonstrating that electron exchange between the 214 
redox probe and the electrode was impeded, and this was enhanced further when BSA was added to the 215 
SPE-graphene/PANI/Ab (Rct = 2.09 KΩ, Fig. 1B). Similar data was obtained for the anti-5mc antibody 216 
sensor platform build (Fig. 1C and D). To define linear ranges for 5mc and acH3 concentrations, Rct 217 
values of genomic DNA (gDNA; 4.8pg/µL - 75ng/µL) and chromatin (8.6pg/µL - 134ng/µL) were 218 
determined (Fig. 2A and B respectively).  219 
 220 
DNA methylation and histone H3 acetylation status in normal and breast cancer cell models 221 
 222 
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Global and locus specific epigenetic profiles were determined for non-cancer (MCF12A) and cancer 223 
derived (MCF7) breast cell lines. EIS demonstrated resistance due to presence of methylated DNA present 224 
in chromatin extracts from MCF7 (e.g., 2630 Ω ± 160 Ω; 75 ng/µL input gDNA) and MCF12A cells (2510 225 
Ω ± 205 Ω; 75 ng/µL input gDNA) (Fig. 3A), consistent with global methylated DNA assessment made 226 
using dot blotting (Fig. 3B). Single locus analysis of a CpG island in the 5’UTR of CXCL12, which 227 
encodes the stromal cell derived factor 1α protein commonly overexpressed in many cancers (Guo et al., 228 
2016), also demonstrated that DNA methylation levels were similar in both normal and cancer breast cell 229 
types (Fig. 3C).  230 
 231 
EIS also enabled direct measurement of global histone H3 acetylation (acH3) in MCF7 cells for e.g., 232 
4460 Ω ± 50 Ω, 134 ng/µL input chromatin which was significantly higher than the levels measured in 233 
MCF12A (3287 Ω ± 589 Ω, 75 ng/µL input chromatin) (Fig. 3D), and this difference was confirmed by 234 
protein blotting (Fig. 3E). Conversely ChIP analysis at the cyclin dependent kinase inhibitor 1 (p21) locus 235 
revealed an 8-fold lower level in acetylation in MCF7 compared to MCF12A cells (Fig. 3F), 236 
demonstrating that whilst globally the MCF7 genome is hyperacetylated compared to MCF12A cells, there 237 
are also locus specific and therefore functional differences between these breast cancer cell types. 238 
Suppression of p21 expression through loss of acetylation results in loss of cell cycle arrest, driving 239 
proliferation, a hallmark of cancer cells, and is therefore expected in the cancer cell line.  240 
 241 
EIS sensor measurements show that global measurement of epigenetic marks can be useful in 242 
differentiating cancer and non-cancer cell types, and that combining epigenetic signatures may be 243 
beneficial. For example, MCF7 (low methylation + high acetylation) can be distinguished from MCF12A 244 
(low methylation + low acetylation). With the addition of other epigenetic marks an algorithm could be 245 
developed to provide a cell specific signature. 246 
 247 
Monitoring global response to decitabine and vorinostat treatments in cancer cell lines. 248 
 249 
Small chemical modifications that trigger chromatin remodeling through processes including DNA 250 
methylation and histone acetylation are of increasing interest as therapeutic targets in cancer diseases due 251 
to reversible nature of these epigenetic modifications (Dawson and Kouzarides, 2012; Flavahan et al., 252 
2017). For example, 5-Aza-2′-deoxycytidine (decitabine) is a strong inducer of DNA de-methylation and is 253 
approved for the treatment of myelodysplastic syndrome (Mossman et al., 2010; Ramos et al., 2015), and 254 
suberoylanilide hydroxamic acid (vorinostat) is a histone deacetylase inhibitor (HDACi) approved for the 255 
treatment of cutaneous T cell lymphoma (Qu et al., 2017). The rapid detection of global epigenetic status 256 
could represent a useful tool for risk assessment, diagnosis, and for treatment monitoring, complementing locus 257 
specific analysis of tumor suppressor and oncogene epigenetic status in patients. 258 
 259 
EIS was used to assess MCF7 and HEC50 cells for response to decitabine and vorinostat treatments (Fig. 4A 260 
and D; Fig. 5A and D). The response of MCF7 cells to decitabine was readily distinguished using EIS 261 
sensors at higher concentrations of input gDNA (≥ 15ng/µL). For example, a ∆Ω between untreated 262 
(2630 Ω ± 160 Ω at 75 ng/µL) compared to treated (2130Ω ± 122 Ω at 75ng/µL) was -500Ω showing an 263 
expected decrease in DNA following treatment. For endometrial cancer cells a similar trend was observed, 264 
for example a mean ∆Ω of -780 at 75ng/µL (Fig. 5A). 265 
 266 
These responses were validated using a methylated DNA specific dot blot, where 100ng total gDNA 267 
extracted from both MCF7 and HEC50 cells showed decreased intensity following treatment (Fig. 4B and 268 
5B), and by MeDIP where the CpG island region of the CXCL12 gene was significantly demethylated. A 269 
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45-fold decrease in DNA methylation was measured by MeDIP in MCF7 cells, whereas in HEC50 only a 270 
3-fold decrease in methylation was observed (Fig. 4C and 5C). 271 
 272 
Acetylated histone H3 was similarly analyzed following exposure of cells to vorinostat. Significantly 273 
increased acetylation was observed in the treated samples compared to untreated controls in both MCF7 274 
and HEC50 with ∆Ω much greater compared to that observed for decitabine treatment (Fig. 4D and 5D). 275 
For MCF7, a ∆Ω of +653 (8173 Ω ± 99 Ω treated, 7520 Ω ± 331 Ω untreated) was measured in MCF7 at 276 
the highest input chromatin concentration of 24.6 ng/µL for untreated and 44 ng/ µL for vorinostat treated, 277 
indicative of an increase in open chromatin architecture. For Hec50, a ∆Ω of +4600 was (7830 Ω ± 90 Ω 278 
treated, 3230Ω ± 38 Ω untreated) was obtained for 83.2 ng/µL for untreated cells and 58 ng/µL for treated 279 
cells). 280 
 281 
Immunosensor performance was also validated by western blotting (Fig. 4E and 5E), and p21 ChIP where 282 
a 2.11 and 3.28 -fold increase in H3 acetylation following vorinostat treatment were measured in MCF7 283 
and HEC50 respectively (Fig. 4F and 5F). 284 
 285 
The use of EIS in monitoring cellular responses to drug treatment is clearly very effective, and such a 286 
monitoring would be of value in determining patient responses to such treatments, particularly if 287 
measurements could be made directly from free circulating methylated DNA and modified chromatin that 288 
are known to alter in patients.  289 
 290 
 291 
4. Discussion  292 
 293 
The adaptation of a graphene based EIS immunosensor has enabled for the first-time direct amplification-294 
free and label-free detection of both DNA- and nucleosome- linked epigenetic modifications. The method 295 
developed here utilizes antibodies that have been validated and widely used for locus specific genome 296 
wide analysis associated with ChIP- and MeDIP- techniques, making comparison between EIS and 297 
epigenomic analysis more robust. The EIS method presents a snapshot of ‘gross’ epigenetic status rather 298 
than the ‘statically global view’ obtained from the assimilation of multi-loci epigenome datasets. The 299 
speed of signal acquisition compared to PCR or DNA sequencing is substantially improved as there is no 300 
requirement for template amplification. Furthermore, the relative simplicity of the analytical process and 301 
very low sample volumes lend this approach to clinical utility. This technology is envisioned to become a 302 
price competitive point-of-care system, where single use functional screen-printed electrodes are 303 
preferable to reusable systems due to the need to minimize false positive results that would likely occur 304 
due to incomplete biological sample removal from the biosensor surface. Future miniaturization of this 305 
technology, as printing techniques become more refined and with higher resolution, will go some way to 306 
reducing the associated waste stream. Current legislation necessitates that clinical samples are correctly 307 
handled of therefore sensor chips exposed to clinical material must be disposed of appropriately. 308 
 309 
Cytosine methylation and gross histone H3 acetylation are regulatory mechanisms for, and established 310 
markers of, transcription repression and activation respectively. DNA methylation directs gene silencing 311 
through the establishment of condensed heterochromatic structures, whereas histone H3 acetylation results 312 
in the loss of association between lysine residues in histone tails and the negatively charged phosphate 313 
backbone of DNA resulting in transition to a euchromatic state. Furthermore, both mechanisms are the 314 
target of currently available therapeutics including decitabine, a cytosine analogue that functions as a DNA 315 
methylase transferase (DNMT) inhibitor. Following its incorporation into DNA during replication, 316 
decitabine irreversible binds to DNMT1, sequestering it the site of interaction and rendering it ineffective. 317 
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Vorinostat is a histone deacetylase (HDAC) inhibitor that binds to the active site in HDAC enzymes, 318 
inhibiting their function, leading to an accumulation of acetylated histones.  319 
 320 
Here we have reported differences between EIS measurements as a ∆Ω value, as the exact amount of DNA 321 
or chromatin present has not been directly determined. However, as total global DNA methylation levels 322 
are estimated to be 0.7 – 2.8 mole percent i.e., moles of 5-methyl cytosine per 100 bases of total DNA in 323 
eukaryotes (Hall, 1971), we estimate for example that 0.52-2.1ng/µL methylated DNA per 75ng/µL input 324 
DNA is being detected in the EIS assay. Similarly, it is estimated that only 1.2% of chromatin is acetylated 325 
at histone H3 (Roh et al., 2005), therefore we are detecting approximately 1.6 ng/µL acetylated histone H3 326 
per 134ng/µL input chromatin. 327 
 328 
DNA methylation levels were similar for normal and breast cancer cell lines tested using EIS suggesting 329 
that global methylation without any selection of genetic loci is not useful in differentiating between the cell 330 
types used in this study. In contrast, the level of global acetylation in the MCF7 cancer cell line was higher 331 
than in the non-cancer MCF12A cells illustrating that, even in the absence of any pharmacological 332 
treatment that can modify cellular epigenetic status, differences can be determined between cell types that 333 
originate from the same tissue. 334 
 335 
Using EIS sensors we were able to trace cellular response to treatments with DNMT or HDAC inhibitors, 336 
monitoring the respective decreases in DNA methylation or increases in histone H3 acetylation. The 337 
response of both breast and endometrial cancer cells to decitabine and vorinostat was as expected with 338 
differentiation between cell responses to either treatment detectable at detectable very low levels of input 339 
DNA or chromatin. With this detection platform available it will now be possible to monitor patient 340 
responses to treatment directly from patient samples.  341 
 342 
With the recent surge in global efforts to map epigenomes across cancer types and patient cohorts (Bock et 343 
al., 2016; Libertini et al., 2016; Rendeiro et al., 2016; Xi et al., 2018) it is becoming possible to associate 344 
global epigenetic changes with disease status using statistical approaches. We propose that multiplex EIS 345 
could be used to simultaneously assess several epigenetics marks, and that such an approach could 346 
accurately diagnose and even stage disease progression directly from patient samples. Such an approach 347 
would obviate the need for DNA sequencing or indeed the complex and ongoing processes of identifying 348 
and characterizing circulating protein biomarkers. The use of a multi-epigenetic marker algorithm coupled 349 
with the ∆Ω differential quantification against known and predetermined/preprogrammed standards 350 
provides an obvious and compelling strategy that now needs to be exploited. 351 
 352 
 353 
5. Conclusions 354 
 355 
Whilst a number of DNA methylation sensors have been reported (Krejcova et al., 2017) no single 356 
platform has yet emerged as a preferred solution for accurate and rapid methylation testing. The use of 357 
biosensors in monitoring changes in global methylation levels in response to cancer cell treatment with 358 
decitabine is reported here for the first time. The development of biosensors for detection of histone 359 
acetylation lags significantly behind that of DNA methylation biosensors, and has to date been limited to 360 
fluorescent based approaches (Wang et al., 2017). The system presented in the current study uses an 361 
antibody-based approach, and employs the same platform used for DNA methylation detection.  Using this 362 
system, we were able to demonstrate for the first-time the amplification and label free immuno-detection 363 
of histone H3 acetylation, and monitor responses of breast and endometrial cancer models to vorinostat, a 364 
drug that has undergone clinical trials for the treatment of advanced breast cancer (Luu et al., 2018). The 365 
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ability to track patient response to both these drugs will have major implications in the management of 366 
their care. 367 
 368 
The combined detection of two different epigenetic marks, using a unified detection platform, now opens 369 
the way to monitoring multiple epigenetic modifications, particularly targeting the multitude of 370 
modifications that occur on histone proteins, which as well as acetylation, include protein methylation, 371 
ubiquitylation, phosphorylation, sumoylation, ribosylation and citrullination. Developments in smaller, 372 
multiplexed sensors are now required, and could result in a move from SPEs to emerging FET-based 373 
systems (Campos et al., 2019). 374 
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 392 
 393 
Fig. S1. Surface characterization of biosensor assembly. (A) Scanning Electron Microscopy of (a) unmodified 394 
graphene; (b) graphene modified with PANI (C); anti-acH3 attached to the PANI layer; (B) Atomic Force 395 
Microscopy of (a) unmodified graphene; (b) graphene modified with PANI (c); anti-acH3 attached to the PANI layer. 396 
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 397 
Fig 1. Electrochemical characterization of biosensor assembly. (A) Cyclic voltammogram (CV) of the acetylation 398 
immunosensor assembly after each modification of graphene-SPE/PANI//anti-acH3/BSA. (B) Nyquist plots of 399 
graphene-SPE/PANI//anti-acH3/BSA sensor, obtained in 5.0mM [Fe(CN)6]3-/4- PBS buffer pH 7.4. (C) CV of the 400 
methylation immunosensor assembly after each modification of graphene-SPE/PANI//anti-5mC/BSA (D) Nyquist 401 
plots of graphene-SPE/PANI/anti-5mC/BSA sensor, obtained in 5.0mM [Fe(CN)6]3-/4- PBS buffer pH 7.4. 402 
403 
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 404 
Fig. 2. Global epigenetic modifications in breast cells (MCF12A). (A) Representative Nyquist plot of the 405 
methylation biosensor upon detection of increasing concentrations of gDNA (B) Representative Nyquist plot of the 406 
acetylation biosensor upon detection of increasing concentrations of chromatin.   407 
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408 
   409 
Fig. 3. Detection of global (A, B, D and E) and locus (C and F) modifications in breast cancer cells. (A) 410 
Calibration curve, plotting log(gDNA) against Rct for MCF12A and CF7. Error bars represent the standard error of 411 
the mean of three biological replicates. (B) Dot blotting of global methylation for MCF12A versus MCF7 using 412 
gDNA with anti-5mC antibody. (C) MeDIP enrichment of CXCL12 from 500 ng MCF12A and MCF7 gDNA by 413 
MeDIP using anti-5mC antibody relative to a non-specific IgG reported as % real signal (% positive antibody - % 414 
IgG, relative to a standard gDNA input sample). Error bars represent the standard error of the mean of three 415 
biological replicates. (D) Calibration curve, plotting log(chromatin) against Rct for MCF12A and MCF7. Error bars 416 
represent the standard error of the mean of three biological replicates. (E) Western blot detection of global acetylated 417 
histone H3 (acH3) in MCF12A and MCF7 chromatin using a specific antibody directed against the modified histone 418 
protein. (F) Enrichment of the human p21 locus associated with acetylated histone H3 by ChIP using 1 µg MCF12A 419 
and MCF7 chromatin. Error bars represent the standard error of the mean of three biological replicates.  420 
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 421 
Fig. 4. Detection of global (A, B, D and E) and locus (C and F) modifications in breast cancer cells (MCF7) 422 
upon treatment. (A) Calibration curve, plotting log(gDNA) against Rct for MCF7 treated versus MCF7 untreated. 423 
Error bars represent the standard error of the mean of three biological replicates. (B) Dot blotting of global 424 
methylation for MCF7 treated versus untreated using gDNA with anti-5mC antibody. (C) MeDIP enrichment of 425 
CXCL12 from 500 ng MCF7 treated and MCF7 untreated gDNA using anti-5mC antibody relative to a non-specific 426 
IgG. Error bars represent the standard error of the mean of three biological replicates. (D) Calibration curve, plotting 427 
log(chromatin) against Rct for MCF7 treated versus MCF7 untreated. Error bars represent the standard error of the 428 
mean of three biological replicates. (E) Western blot detection of global acetylated histone 3 (acH3) in MCF7 treated 429 
versus untreated chromatin using a specific antibody directed against the modified histone protein. (F) Enrichment of 430 
the human p21 locus associated with acetylated histone H3 by ChIP using 1 µg MCF7 treated and MCF7 untreated 431 
chromatin. Error bars represent the standard error of the mean of three biological replicates.  432 
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 434 
Fig. 5. Detection of global (A, B, D and E) and locus (C and F) modifications in endometrial cells (Hec50) upon 435 
treatment. (A) Calibration curve, plotting log(gDNA) against Rct for Hec50 treated versus Hec50 untreated. Error 436 
bars represent the standard error of the mean of three biological replicates. (B) Dot blotting of global methylation for 437 
Hec50 treated versus Hec50 untreated using gDNA with anti-5mC antibody. (C) MeDIP enrichment of CXCL12 438 
from 500 ng Hec50 treated and untreated gDNA by MeDIP using anti-5mC antibody relative to a non-specific IgG 439 
demonstrates. Error bars represent the standard error of the mean of three biological replicates. (D) Calibration curve, 440 
plotting log(chromatin) against Rct for Hec50 treated versus Hec50 untreated. Error bars represent the standard error 441 
of the mean of three biological replicates. (E) Western blot detection of global acetylated histone 3 (acH3) in Hec50 442 
treated versus Hec50 untreated chromatin using a specific antibody directed against the modified histone protein. (F) 443 
Enrichment of the human p21 locus associated with acetylated histone H3 by ChIP using 1 µg Hec50 treated 444 
untreated chromatin. Error bars represent the standard error of the mean of three biological replicates.  445 
 446 
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Highlights  
 
• Label and amplification-free graphene electrochemical immunosensor for the direct global assessment of 
methylated DNA and histone H3 acetylated chromatin levels.  
• System application demonstrated global alterations in DNA methylation or histone H3 acetylation in 
response to treatment with decitabine and vorinostat respectively.  
• Results were corroborated using established techniques including ChIP and MeDIP.  
• The study opens up the opportunity for assessing point-of-care monitoring of patient responses to 
epigenetic therapeutics, and multiplexing epigenetic marker detection on a unified platform. 
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